ICER Announces Plans to Assess Sickle Cell Gene Therapy
November 23, 2022
Two sickle cell gene therapies will be assessed for value and efficacy by the Institute for Clinical and Economic Review (ICER), according to an announcement today, November 23rd. The institute will investigate lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) and exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics). Public discussions will take place at a June 2023 CTAF meeting.
According to ICER, “All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to publiccomments@icer.org and must be received by 5 PM ET on December 15, 2022. Please submit public comments as a Word document in the following format:”
To read more, click here.
(Source: ICER, November 23rd, 2022)